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Physical Therapy with Drug
Treatment in Bell Palsy
A Focused Review
ABSTRACT
Ferreira M, Marques EE, Duarte JA, Santos PC: Physical therapy with drug
treatment in bell palsy: a focused review. Am J PhysMed Rehabil 2015;94:331Y340.
The physical therapy (PT) associated with standard drug treatment (SDT) in Bell
palsy has never been investigated. Randomized controlled trials or quasirandomized
controlled trials have compared facial PT (except treatments such as acupuncture
and osteopathic) combined with SDT against a control group with SDT alone. Partic-
ipants included those older than 15 yrs with a clinical diagnosis of Bell palsy, and
the primary outcome measure was motor function recovery by the House-Brackmann
scale. The methodologic quality of each study was also independently assessed by
two reviewers using the PEDro scale. Four studies met the inclusion criteria. Three
trials indicate that PT in association with SDT supports higher motor function
recovery than SDTalone between 15 days and 1 yr of follow-up. On the other hand,
one trial showed that electrical stimulation added to conventional PT with SDT did
not influence treatment outcomes. The present review suggests that the current
practice of Bell palsy treatment by PTassociated with SDT seems to have a positive
effect on grade and time recovery compared with SDT alone. However, there is
very little quality evidence from randomized controlled trials, and such evidence is
insufficient to decide whether combined treatment is beneficial in the management
of Bell palsy.
Key Words: Rehabilitation, Facial Muscle Recovery, House-Brackmann, Randomized
Controlled Trial, Physical Therapy
Idiopathic peripheral facial nerve palsy or Bell palsy (BP) refers to an acute onset of
lower motor neuron type of facial paralysis (complete palsy) or paresis (partial
palsy), resulting in an inability to control facial muscles on the affected side. BP is
the most frequent form of peripheral palsy of the facial nerve, and the reported
annual instance is between 11 and 53.3 new cases per 100,000 persons.1,2 It leads to a
considerable disturbance in social activities.3 The etiology of BP is unknown, but it is
widely accepted as being due to the reactivation of latent herpes simplex type 1 virus
within geniculate ganglion, followed by the ethiopathologic mechanism that involves
inflammation and entrapment of the nerve at the meatal foramen that leads to
demyelination of the axons and possible ischemia by disruption of blood supply.4,5
The aims of any treatment in acute-stage BP are to promote speedy recovery
and prevent sequelae. Thus, the most effective evidence-based treatment that entails
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the fewest side effects or risks should be prescribed.
Considerable knowledge has been accumulated con-
cerning the significance of pharmacologic treat-
ment based on the presumed pathophysiology of BP,
namely, inflammation and viral infection. On the
basis of evidence, some physicians prescribe corti-
costeroids as a primary treatment because of their
potential to reduce swelling and inflammation,
whereas the aim of antiviral treatment is to inhibit
herpes simplex type 1 virus replication through
viral DNA polymerase. Several studies have dem-
onstrated somewhat conflicting results about the ef-
fectiveness of corticosteroids only or combined with
antiviral treatment. The meta-analysis by Nunthavaj
et al.6 suggests that corticosteroids combined with
antiviral treatment may lead to slightly higher recov-
ery rates at 3 and 6 mos compared with treating with
corticosteroids only, although this difference is not
statistically significant. Corticosteroids remain the
strongest evidence-based monotherapy treatment,
whether compared with placebo or antiviral treat-
ment.6,7 On the other hand, one systematic review8
included three studies with 117 patients who dem-
onstrated no benefit from using corticosteroids only
compared with placebo/vitamin. The American Col-
lege of Neurology currently recommends the use of
oral corticosteroids only.9
For the past decades, some methods and
physical agents of facial physical therapy (PT),
such as functional neuromuscular reeducation
associated with or without mirror, mime therapy,
electrical stimulation, surface electromyography
biofeedback, and video self-modeling, have been
used to treat facial paralysis, but the significance of
PT is controversial.10Y12 Most previous studies
evaluated the effects of PT or drug therapy only.
Thus, the combined effect of PT with corticoste-
roids and/or antivirals on patients’ recovery rates
has been poorly investigated. In addition, it should
be highlighted that BP has a high rate of sponta-
neous recovery, thus making it difficult to establish
a strong cause-effect association between treatment
and recovery, even in controlled trials. Peitersen13
suggested a favorable prognosis of spontaneous re-
covery within 3 wks in 85% of patients, and 70% had
a complete recovery within 6 mos. However, patients
with inappropriate treatment may experience long-
standing paralysis and develop sequelae, contractures,
partial recovery of motor function, and synkinesis,
affecting 31% of BP patients.14
The conclusion of the literature review was
that, although standard drug treatment (SDT) seems
to reduce edema and secondary inflammation dam-
age, it does not influence the amount of long-term
damage. As the only alternative to no treatment, PT
seems to be effective in improving facial expression
and function. Strategies of PT have been developed
to control the symmetry of the face, through slow
movements and voluntary control of synkinesis, par-
ticularly with specific exercises. The central question
in this research is, BDo PT and SDT have positive ef-
fects on grade and time recovery in BP?[ Given the
emergence of this clinical practice and lack of evi-
dence of the benefits, this is the first systematic re-
view to present the evidence for prescribing PT
associated with SDT.
METHODS
Criteria for Considering Studies for
This Review
Studies and Participants
A study was included in the review only when
the following criteria were met: (1) there were
randomized trials (RCTs) or quasi-RCTs, (2) the
study population consisted of patients diagnosed
with BP of all degrees of severity, (3) the efficacy of
PT plus drugs treatment was evaluated, (4) there
were at least 15 days of follow-up, (5) the outcome
measure was motor function recovery by a recog-
nized scoring system such as the House-Brackmann
(HB) facial grading system,15,16 (6) there was a
comparative control group (CG), and (7) it included
adults older than 15 yrs. The authors did not in-
clude studies on pregnant women, patients ex-
periencing recurrent or bilateral BP, and studies
comparing PT or drugs therapy only. No language
restrictions were used.
Types of Interventions
Included studies compared interventions with
any PT (except acupuncture and osteopathic) com-
bined with SDT (corticosteroids and/or antiviral
agents) against a CG. The accepted intervention in
the comparison group was SDT only or SDT (sim-
ilar in the experimental group [EG]) plus a dis-
tinctive PT to assess which PT technique is the most
beneficial. PT in BP can include functional neuro-
muscular reeducation with or without mirror,
mime therapy, video self-modeling, electromyog-
raphy biofeedback, and electrical stimulation with
or without thermal or massage agents.
SDT was accepted if administered orally and
started immediately after the diagnosis of BP.9,17,18
Types of Outcome Measures
The primary outcome of the present study
was complete or partial facial muscle recovery, de-
fined by HB grade 1 or 2. This scale analyzes the
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symmetry, synkinesis, stiffness, and global mobility
of the face. It is divided into six categories (normal,
mild dysfunction, moderate dysfunction, moder-
ately severe dysfunction, severe dysfunction, and
total paralysis) and is a 1- to 6-point scale with 6
representing total paralysis.15,16
Secondary outcome measures were adverse
events (side effects of interventions); compoundmotor
action potential amplitude and percentage activity
as measured in the orbicular oculi and frontal and
orbicular oris muscles, the both sides of the face
[(electroneurography (%) = 100 - 100*(amplitude on
the affected side/amplitude on the healthy side)];
no residual symptoms (synkinesis, hemifacial spasm,
contractures, epiphory); and Sunnybrook facial grad-
ing system (SB). The SB system has three components
of facial asymmetry: resting asymmetry (scored from
0/asymmetry to 4/symmetry), symmetry of voluntary
movement (0/asymmetry, 5/symmetry), and synkinesis
(0/better, 3/worst).19 A total score of 100 points rep-
resents normal facial symmetry.
Search Methods for Identification of Studies
The search strategy was applied to the following
databases: MEDLINE, Academic Search Complete,
MedicLatina, CINAHL, SPORTDiscus, Scopus, and
PEDro from their inception to August 1, 2013. The
search method incorporated National Library of
MedicineMedical Subject Headings,20 combining the
following terms: (1) type of disease, Bidiopathic
facial palsy[ or Bfacial paralysis[ or BBell’s palsy,[
and (2) types of intervention, Bphysical therapy[ or
Bphysiotherapy[ or Bmime therapy[ or Bexercise
movement techniques[ or Bfacial exercises[ or Bfacial
expression[ or Bphysical rehabilitation[ or BBio-
feedback[ or Belectrical stimulation[ or Bmassage[
and [Bdrug therapy[ or Banti-viral agents[ or
Bacyclovir[ or Bvalacyclovir[ or Bfamciclovir[ or Banti-
inflammatory agents[ or Bcortisone[ or Bprednisone[
or Bcorticosteroids[ or Bsteroids[].
Selection of Studies and Data Extraction
Abstracts and full texts identified by comput-
erized database searches were screened by two re-
viewers (MF, JD), using predetermined eligibility
criteria to ascertain potentially relevant trials to be
included in the review, as defined in the National
Health and Medical Research Council classification
guidelines.20,21All relevant information was col-
lected in data extraction form, which included the
following: study design, authors and year of publi-
cation, country and setting, sample size, patient
demographics, number of patients in each treat-
ment group, type of antiviral and/or steroids used
and dose, type and frequency of PT, length of follow-
up, type of facial muscle recovery outcome scale
used, definition for facial recovery, proportion of
patients with facial recovery at each follow-up time
point, and methodologic quality of included stud-
ies. Disagreements regarding trial eligibility were
FIGURE 1 Flow diagram of the study selection process.
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resolved by discussion and consultation by a third
reviewer (ME).
Assessment of Methodologic Quality
The PEDro scale was used to rate the metho-
dologic quality of each study. The scale contains 11
items, of which ten items assess internal validity.22,23
One criterion was omitted among the studies (eligi-
bility criteria), because such criterion refers to the
generalization of the results. Each item was graded
0 or 1 (point), with a maximum score of 10 points.
PEDro scores were interpreted as follows: a score of
9 or more indicated excellent methodologic quality,
6Y8 was good methodologic quality, 4Y5 was fair
methodologic quality, and G4 was poor methodologic
quality. Two reviewers (MF, JD) assessed quality in-
dependently. Any disagreement between the two re-
viewers was discussed and resolved by consensus with
a third author (EM).
RESULTS
Description of Studies
Selected Studies
The search strategy retrieved 252 abstracts (Fig. 1).
As some studies were found inmore than one database,
duplicates were removed. A total of 244 studies were
excluded because they did not match the inclusion
criteria. Of these, eight trials were identified as highly
relevant, although four were subsequently excluded:
one study24 compared the intervention with predni-
sone alone vs. PT alone, another study25 used different
outcome measures, another study26 did not include
SDT, and the last analyzed the effect of antiviral
treatment.27 Four studies satisfied the inclusion
criteria and were included in the current review.
Included Studies
In total, four studies28Y31 were included in the
systematic review (Table 1). Of these, three studies28Y30
TABLE 1 Characteristics of included studies
Study Country, Setting Participants
Nicastri et al.28 (2013) Italy University Hospital
BUmberto I[
Total of 87 patients with severe grade (HB Q IV)
on the tenth day after the onset of palsy;
follow-up, 6 mos; CG, 48 patients (22 men,
26 women); age, 51.3 yrs; EG, 39 patients
(22 men, 17 women); age, 47.1 yrs
Barbara et al.29 (2010) Italy University Hospital
BSant´Andrea[
Total of 20 patients with moderate-to-severe
grade (HB Q 3) on the third day after onset,
follow-up of 2 wks; CG (nonrehabilitation),
11 patients (five men, six women); age, 42 yrs;
EG (rehabilitation), nine patients (five men,
four women); age, 35 yrs
Penteado et al.30 (2009) Sa˜o Paulo (South America)
Hospital University
Total of 20 patients with moderate-to-severe
grade (HB Q IIIYV) on the fourth mo of the
episode of BP were followed for 1 yr; CG,
ten patients (18Y60 yrs); EG, ten patients
(18Y60 yrs)
Alakram et al.31 (2010) South Africa Hospital
Complex (three hospitals)
Total of 16 patients in early stages of BP,
follow-up of 3 mos; CG, eight patients
(three men, five women); age, 41.4 yrs;
EG, eight patients (five men, three
women); age, 3.6 yrs
334 Ferreira et al. Am. J. Phys. Med. Rehabil. & Vol. 94, No. 4, April 2015
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
evaluated SDT (corticosteroids + antiviral agents)
plus PT vs. SDT alone. The other study31 evaluated
a monotherapy drug (prednisolone) plus conven-
tional PT vs. prednisolone plus conventional PT and
electrical stimulation.
The four trials included an overall sample of
143 patients (between 16 and 87 patients). The length
of follow-up varied between studies and ranged from
2 wks to 12 mos. Trials were conducted in three coun-
tries and on three continents. Three studies28,29,31
were published in English, and one study30 was pub-
lished in French.
The study by Nicastri et al.28 was designed for
6 mos, was single-blind, and was an RCT. It in-
cluded 87 patients with BP, distributed in two
treatment groups: an EG (39) received SDT (pred-
nisone + valacyclovir) combined with PT, and the
CG (48) received SDT. The eligibility criteria were as
follows: age between 15 and 70 yrs, unilateral BP
clinically diagnosed, and severe (grades IVYVI) facial
palsy assessed by HB on the tenth day after the
initial symptoms of BP. Both groups were treated
with oral prednisone (1 mg/day for 10 days) plus
valacyclovir (500 mg three times per day for 6 days).
In addition, the EG was treated with a neuromus-
cular retraining program that consisted of facial
muscle physiology and massage education, active
motion exercises with or without mirror feedback,
stretching, and specific facial exercises. Each pa-
tient of EG was treated in the outpatient clinic by
means of individual sessions lasting 45 mins each,
twice a week for the first 3 mos and once a week
thereafter, until the follow-up was completed. All
patients were assessed by HB on their first visit to
the clinic, 10 days thereafter, and then monthly
until the end of follow-up (6 mos).
Barbara et al.29 published a study of a random-
ized trial: 20 patients with moderate- to severe-grade
Interventions Outcome Results/Conclusions
CG: patients who received only SDT (oral
prednisone of 1 mg/10 days + valacyclovir
of 500 mg three times a day for 6 days).
EG: patients who received the same SDT
plus PT (neuromuscular retraining program
with or without mirror feedback; individual
sessions lasting 45 mins each/two times a
week for the first 3 mos and once a week
thereafter, until the follow-up was completed
or at the end of the 6 mos).
The primary outcome was the
HB-FGS (reaching a grade
of II or less). The secondary
outcomes were the time to
reach a HB-FGS grade of II
or less, the differences over
time in the mean SB-FGS
total score, and the proportion of
patients having a synkinesis
subscore of 0 (i.e., no synkinesis).
The results demonstrated that
the EG experienced a
significant effect in grade and
time to recovery only among
patients presenting with
severe facial palsy (HB grade
V/VI). The reduction of
synkinesis was not significant
between the groups.
CG: patients were submitted to SDT (oral
prednisolone of 40 mg/day for 10 days and
then tapered within the next 5 days +
acyclovir of 400 mg three times per day
for 15 days). EG: patients received the
same SDT and Kabat rehabilitation or
proprioceptive neuromuscular
facilitation (stretching, maximal resistance,
manual contact, verbal input).
HB-FGS (grades I and II) and
electroneurography (amplitude
of the compound motor action
potential); normal range was
considered to be between
2 and 4.5 mV.
Kabat rehabilitation patients
achieved a better and faster
recovery in comparison
with nonrehab patients,
in early stages.
CG: received SDT (oral prednisone of 1 mg/day
for 15 days + valacyclovir of 500 mg three
times a day for 5 days). EG: patients received
the same SDT and rehabilitation facial or
Chevalier method, which consisted of analytic
muscle exercises and undesirable movement
inhibition by stretching, for 15 mins, two times
per day and five-to-ten repetitions for each
exercise, from days 1 to 15 after symptom onset.
HB-FGS (grades I
and II), SB-FGS
The facial rehabilitation
method described by
Chevalier showed
improvement in function
recovery than CG.
CG: patients were treated with drug
monotherapy (oral prednisolone of 2 mg
daily) weaned off within 2 wks and combined
conventional PT (5 mins of hot packs,
10 mins of massage, and ten repetitions
of exercises once a week/home exercise).
EG: patients received the same drug
monotherapy and conventional PT with
electrical stimulation (30 mins/TENS unit).
HB-FGS (recovery
defined, 80%)
The improved percentage
of HB-FGS in the EG
was not significant
compared with the CG.
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(HB Q IIIYVI) early-stage BP who submitted to SDT
(prednisolone + acyclovir) for 15 days were included.
Drugs treatment was immediately started, combining
oral prednisolone (40 mg/day for 10 days and then
tapering off within the next 5 days) plus acyclovir
(400 mg three times per day for 15 days). After that,
they were divided into two groups. The rehabilita-
tion group (rehab group) of nine patients under-
went Kabat rehabilitation with one session per day for
6 days, sustained for 15 days. The nonrehabilitation
group (nonrehab group) of 11 patients did not submit
to physical rehabilitation. Kabat rehabilitation or pro-
prioceptive neuromuscular facilitation started from day
4 after BP onset and included stretching, maximal re-
sistance,manual contact, and verbal input. Thismethod
considers the harmony, coordination, and optimal
strength of body movements through a global pattern.
The evaluation was carried out by measuring the am-
plitude of the compound motor action at days 4, 7, and
15 after onset of BPaswell as by observinggradeHouse-
Brackmann within 3, 4, 7, and 15 days.
Penteado et al.30 had 20 patients with moderate-
to-severe grade (HB Q IIIYV) on the fourth month
after onset of BP, who were followed for 1 yr. All
patients received SDT oral prednisone (1 mg/kg/day
for 15 days) plus valaciclovir (500 mg three times per
day for 5 days). The EG included ten patients treated
according to the facial rehabilitation method de-
scribed by Chevalier between the 1st and 15th days
after the installation of BP and having developed se-
quelae during their recovery. Facial rehabilitation
consisted of analytic muscle exercises on the palsy
face and inhibition of undesirable movements by
stretching. The CG received a nonrehabilitation fa-
cial. All patients were evaluated weekly during the
first month and then monthly until the end of the
study by HB and SB scales.
The study conducted by Alakram and Puckree31
had 16 patients with BP with less than 30-day dura-
tion, randomized into two intervention groups with
eight patients each. Both groups were treated with
oral prednisolone (2 mg/kg daily, weaned off within
2 wks). The researcher treated each patient in both
groups (CG and EG) with 5 mins of heat, 10 mins
of massage, and ten repetitions of exercises once a
week, and each patient was also given an illustrated
home exercise handout with instructions: ten repe-
titions of each exercise, three times daily. The EG also
received electrical stimulation of the facial muscles
(30 mins/pulse and frequency of 10 Hz/pulse width
and duration of 10 Ksecs). All patients were objec-
tively evaluated with the HB scale until recovery, for
a maximum of 3 mos after onset of BP.
Methodologic Quality of the Studies
PEDro scores ranged between 2 and 8 (Table 2),
with one study28 considered to have good meth-
odologic quality (i.e., PEDro score of 6Y8). All
studies28Y31 were conducted with no blind patients,
therapists, and concealed allocation, which reduced
the maximum score achieved. On the other hand,
all studies28Y31 satisfied the criteria of baseline simi-
larity between groups and point estimates and vari-
ability. Three studies28Y30 observed the follow-up of
greater than 85%, and two studies30,31 did not use
random allocation.
Effects of Interventions
Primary Outcome Measure
All studies reported satisfactory recovery for PT
and medical treatment. Nicastri et al.28 showed that
the EG (PT plus SDT) had a significant effect in
function recovery (P = 0.038) and time of recovery
(P = 0.044) compared with the CG (SDT) on patients
with HB grade V/VI, at the end of the 6-mo follow-
up period.
The study by Barbara et al.29 showed that the
rehabilitation group (Kabat rehabilitation combined
with SDT) had significant improvement only at day
TABLE 2 Methodologic quality of studies
PEDro Criterion
Study 1 2 3 4 5 6 7 8 9 10 11 Total/10
Nicastri et al.28 (2013) 1 1 0 1 0 0 1 1 1 1 1 7/10
Barbara et al.29 (2010) 1 1 0 0 0 0 0 1 0 1 1 4/10
Penteado et al.30 (2009) 1 0 0 1 0 0 0 1 0 1 1 4/10
Alakram et al.31 (2010) 1 0 0 0 0 0 0 0 0 1 1 2/10
PEDro criteria: (1) eligibility criteria, (2) random allocation, (3) concealed allocation, (4) baseline comparability, (5) blind
subjects, (6) blind therapists, (7) blind assessors, (8) follow-up 9 85%, (9) intention-to-treat analysis, (10) between-group com-
parisons, and (11) point estimates and variability.
Item scoring: 1, present; 0, absent. Criterion 1/eligibility criteria does not contribute to total score.
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15 (P = 0.028) compared with the nonrehabilitation
group (SDT). At day 15, the worst grade of paralysis
was HB III and affected 44% of the rehab group,
whereas 10% of patients in the nonrehab group were
affected by HB V. Conversely, HB grade I (normal
function) was observed in 22% of the rehab group
and in 20% of the nonrehab group.
The Penteado et al.30 study showed better facial
recovery of motor function (HB, 87 values or grades
I and II) with the Chevalier method plus SDT
compared with SDT (HB, 69 or grades III and IV).
Alakram and Puckree31 compared two inter-
ventions and reported rate recovery of motor function
in the CG between 17% and 50% with a mean of
30%,whereas that for theEG ranged from17% to 75%
with a mean of 37%. The difference between the
groups was not statistically significant (P = 0.36).
Secondary Outcome Measure
The Nicastri et al.28 study reported a significant
difference between two groups for SB final scores:
60 and 79 values for the CG and EG, respectively
(P = 0.021).
The Barbara et al.29 study showed no signifi-
cant variation in compound motor action potential
amplitude.
The Penteado et al.30 study revealed a difference
between groups for SB final scores: 89 values for the
Chevalier method plus medical treatment group and
69 values for medical treatment.
Residual Symptoms
Nicastri et al.28 demonstrated that synkinesis
was found in 25 patients (29%), and in most cases, it
started after the fourth month of follow-up. There
were no differences between the two treatment
groups in the proportion of patients with a
synkinesis subscore of 0 at the end of the study
period.
The Penteado et al.30 study also showed that
sequelae were developed approximately the fourth
month after onset of palsy, in both groups.
Three studies29Y31 did not evaluate synkinesis.
Adverse Events
All studies did not report side effects of phar-
macologic treatment, but Sullivan et al.18 reported
peptic ulceration, hypertension, and state-of-
confusion effects.
DISCUSSION
Many physicians prescribe antiviral and steroid
drugs to treat BP, despite the unclear benefits of
antiviral therapy.32 Recent evidence from large RCTs
indicates that the complete recovery rate with oral
prednisolone is approximately 85%Y94% within
9Y12 mos.18,33 In the present review, all studies28Y31
had anti-inflammation interventions (prednisone or
prednisolone), administered within 48Y72 hrs of the
onset of BP. In opposition tomedical treatment, PT is
an alternative and is one of the most commonly used
in clinical practice. This review included modalities
of facial rehabilitation in the form of Kabat29 and
Chevalier,30 electrical stimulation,31 neuromuscular
retraining28 with or without massage, and hot pack.
The efficacy of facial rehabilitation has been shown in
patients with permanent sequelae or long-standing
facial paresis (at least 9 mos) by several observational
studies.34Y37 In contrast, the efficacy of facial reha-
bilitation in early/acute stages is more complex to
calculate because of the high rate of spontaneous
recovery.13 Presently, there are scarce studies about
conservative treatment in the early stage of BP.38,39
Three systematic reviews11,12 demonstrated that the
idealmodality of PT has not yet been established or that
no clear consensus exists. According to the previous
literature, reviews focused on the monotherapy of SDT
or PT effects of interventions, and so the combined
therapy effects of interventions remain unknown.
In the present systematic review, three studies28Y30
indicate that facial rehabilitation associated with SDT
is slightly superior in recovery of motor function
than SDT alone. One RCT28 showed a significant
effect on grade and time to recovery in patients
presenting with severe BP (HB Q IV) compared with
SDT alone. In addition, through secondary out-
comes, two studies28,30 reported significant facial
symmetry by Sunnybrook with the neuromuscular
retraining and rehabilitation method described by
Chevalier. Only one study28 showed that combined
treatments are effective in fighting synkinesis. On
the other hand, one study31 did not find the kind of
technique in PT for the recovery motor function of
BP; this study concluded that electrical stimulation
did not greatly influence the recovery rate of BP.
Thus, the studies covered in this systematic
review support improvements with respect to drugs
treatment, which might include the following:
(1) Corticosteroids reduce the inflammatory pro-
cess in BP, and this facilitates remyelination of
the facial nerves. This theory made good
physical sense based on the length of the canal
and relatively small caliber and subsequent
decompression of the nerve.6,18
(2) The addition of antiviral treatment such as
acyclovir or valacyclovir is aimed at the eradi-
cation of herpes simplex type 1 infection.6,7
www.ajpmr.com Physical Therapy and Drugs Therapy in Bell Palsy 337
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
This prescription therapy is based on primary
etiology; it is quite plausible when it involves
the viral agents’ herpes simplex type 1 or
varicella-zoster virus.
In addition, the possible explanations for the
incremental effects of PT might include the
following:
(1) External feedback techniques such as specific
instructions andmirror are adjuvant techniques
to control the correct pattern of responses that
the patient will learn to self-regulate.40
(2) Soft-tissue mobilization and hot pack preserve
muscle trophism, increase circulation, and reduce
involuntary contraction induced by relaxation.14
(3) Electrical stimulation has been discouraged in
the early stages of BP to avoid potential in-
terference with neural regeneration.39 It is
difficult to produce an isolated contraction of
the facial muscles using electrical stimulation
due to their small size and close proximity to
each other. The contraction produced causes
mass action, which reinforces abnormal motor
patterns and can be painful.41,42
(4) The neuromuscular rehabilitation, Kabat and
Chevalier rehabilitation, included the active as-
sistive movement to guide the movement pat-
tern and to promote axonal regeneration by
improving the neuronal connection and facili-
tating new motor patterns.43 Owing to the lack
of somatosensory afferents that constitute the
main intrinsic feedback in relearning move-
ments is particularly important in facilitating
the proprioceptive inputs by PT techniques.44
(5) The stretching can influence the length-
tension relationship of muscles, avoiding
mass movement patterns and synkinesis.44
These combined modalities of BP should be
centralized in the degenerative lesion of the facial
nerve, which may be the most important risk factor
for incomplete recovery. The time course for im-
provement and the extent of recovery are signifi-
cantly different in patients presenting with an
incomplete (paresis) at the onset of BP. Patients
with incomplete BP should start to improve their
facial function within 1Y2 wks after onset of BP and
are expected to recover completely within 3 wks.13
These patients have a spontaneous recovery of BP; it
does not seem that any treatment adds benefits
because of the only partial degeneration and
blocking of nerve conduction (neuropraxia).13 One
study31 included patients with slight dysfunction in
the onset of BP (corresponding HB = II), which
showed improvement in function recovery after
2 wks, and no significant differences between the
groups. On the other side, in the patients’ subgroup
with moderate-to-complete paralysis (correspond-
ing HB grade Q III) at the onset of BP, complete
recovery is more uncertain. Optimum therapy re-
mains a crucially important issue for the 30% of
patients who experience a varying degree of com-
plications, including permanent paresis, pain, and
synkinesis, which can be highly stressful.45 Three
studies28Y30 demonstrate that PT plus SDT ap-
proaches seem to be more effective in the severe and
early/acute stages of BP.
Limitations
To the authors’ knowledge, this is the first
systematic review examining the effectiveness of
combined PT with SDT in the early stage of BP.
First, as with any systematic review, there is the
potential for selection bias; however, the authors
used an ample search strategy in which the authors
included publications in any language as well as in-
dependent reviewers; exclusion criteria were clearly
documented.
Second, the PEDro scores were lowered by a
lack of insufficient randomization and allocation
concealment; appropriate blinding of patients,
therapists, and assessors; and substantial losses in
intention-to-treat analysis. Third, there was het-
erogeneity among studies, particularly the sample
size, grades severity at baseline, time of duration of
the intervention, delay in receiving treatment of PT,
and different types of modalities. Finally, a few
studies were included. This diversity prevented us
from conducting a meta-analysis and highlights the
need for further research.
CONCLUSIONS
The present review suggests that the current
practice of BP treatment by PT associated with SDT
seems to have a positive effect on grade and time
recovery compared with SDT alone. However, there
is very little quality evidence from RCTs, and this is
insufficient to decide whether combined treatment
is beneficial in the management of Bell palsy. Fur-
ther research is required to evaluate the efficacy of
PT associated with SDT and to determine the better
modality to reduce the time of recovery and oc-
currence of synkinesis.
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